NCT05620914 - A Window of Opportunity Study of Patritumab Deruxtecan in Patients With Brain Metastases | Biotech Hunter

Timeline

Start Date

July 31, 2025

Primary Completion Date

April 30, 2026

Study Completion Date

April 30, 2027

Conditions

Brain Metastases, Adult

Interventions

DRUG

Patritumab deruxtecan

Patritumab deruxtecan (HER3-DXd) will be administered IV 5.6 mg/kg as a single dose 1-3 days prior to planned craniotomy and resection of brain metastasis

Trial Locations (1)

27710

Duke University Medical Center, Durham